Eftilagimod alpha
- Generic Name
- Eftilagimod alpha
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy
Phase 2
Active, not recruiting
- Conditions
- Breast Carcinoma
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 849
- Registration Number
- NCT05747794
- Locations
- 🇺🇸
The Oncology Institute, Whittier, California, United States
🇺🇸The George Washington University Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Phase 2
Active, not recruiting
- Conditions
- HNSCC
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 171
- Registration Number
- NCT04811027
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Alabama at Birmingham (UAB) - O'Neal Cancer Center, Birmingham, Alabama, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
Phase 1
Withdrawn
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Immutep S.A.S.
- Registration Number
- NCT04252768
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Phase 2
Completed
- Conditions
- NSCLCHNSCC
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 187
- Registration Number
- NCT03625323
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath